Kymera Therapeutics

Kymera Therapeutics

Kymera Therapeutics

Kymera Therapeutics is pioneering a transformative new approach to treating previously untreatable diseases.
Type
B2c
Raised
$197M
Follow us
Alexa global traffic share
Twitter followers
Latest funding Show all
$102,000,000
Venture capital (Series C) - 2020
Redmile Group BlackRock Wellington Management +4
$65,000,000
Venture capital (Series B) - 2018
Bessemer Venture Partners Pfizer Ventures 6 Dimensions Capital
Team Size
10+
Employees
Xconomy

Kymera Therapeutics Unveils IPO Pitch for Protein Degradation

$102,000,000 Venture capital (Series C)
FinSMEs

Kymera Therapeutics Raises $102M in Series C Financing

$65,000,000 Venture capital (Series B)
PE HUB

Kymera Therapeutics attracts $65 mln Series B